Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 19/20 | 0.75 |
| ▸ | HTR2C | P28335 | 9/20 | 0.59 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.54 |
| ▸ | LCK | P06239 | 1/20 | 0.51 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL884110 | 0.96 | HTR2A (0.79) | HTR2AHTR2CKCNH2 | |
| SCHEMBL884074 | 0.92 | HTR2A (0.74) | HTR2AHTR2CKCNH2 | |
| SCHEMBL2064645 | 0.92 | HTR2A (0.74) | HTR2AHTR2CKCNH2 | |
| SCHEMBL884156 | 0.92 | HTR2A (0.69) | HTR2AHTR2CKCNH2LCKMAPK14 | |
| SCHEMBL2064098 | 0.91 | HTR2A (0.70) | HTR2AHTR2CKCNH2 | |
| SCHEMBL2064360 | 0.91 | HTR2A (0.69) | HTR2AHTR2CKCNH2 | |
| SCHEMBL2066322 | 0.89 | HTR2A (0.74) | HTR2AHTR2CKCNH2 | |
| SCHEMBL883996 | 0.89 | HTR2A (0.71) | HTR2AHTR2CKCNH2LCKMAPK14 | |
| SCHEMBL1167418 | 0.88 | HTR2A (0.70) | HTR2AHTR2CKCNH2LCKMAPK14 | |
| SCHEMBL15788651 | 0.87 | HTR2A (0.85) | HTR2AHTR2CKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3395816-A1 | ETHERS, SECONDARY AMINES AND DERIVATIVES THEREOF AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | Arena Pharmaceuticals, Inc. (US) | 2018-10-31 | — | — | EP | claimed |
| US-9221755-B2 | Ethers, secondary amines and derivatives thereof as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2015-12-29 | — | — | US | claimed |
| US-20140163032-A1 | ETHERS, SECONDARY AMINES AND DERIVATIVES THEREOF AS MODULATORS OF THE 5-HT 2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2014-06-12 | — | — | US | claimed |
| US-8680119-B2 | Ethers, secondary amines and derivatives thereof as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2014-03-25 | — | — | US | claimed |
| US-20120295938-A1 | ETHERS, SECONDARY AMINES AND DERIVATIVES THEREOF AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. | 2012-11-22 | — | — | US | claimed |
| US-20090186895-A1 | ETHERS, SECONDARY AMINES AND DERIVATIVES THEREOF AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2009-07-23 | — | — | US | claimed |
| US-20200247755-A1 | ETHERS, SECONDARY AMINES AND DERIVATIVES THEREOF AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. | 2020-08-06 | — | — | US | disclosed |
| US-20200247755-A1 | ETHERS, SECONDARY AMINES AND DERIVATIVES THEREOF AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. | 2020-08-06 | — | — | US | disclosed |
| US-10450276-B2 | Ethers, secondary amines and derivatives thereof as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2019-10-22 | — | — | US | disclosed |
| US-10450276-B2 | Ethers, secondary amines and derivatives thereof as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2019-10-22 | — | — | US | disclosed |
| EP-3395816-A1 | ETHERS, SECONDARY AMINES AND DERIVATIVES THEREOF AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | Arena Pharmaceuticals, Inc. (US) | 2018-10-31 | — | — | EP | disclosed |
| US-20170166533-A1 | ETHERS, SECONDARY AMINES AND DERIVATIVES THEREOF AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. | 2017-06-15 | — | — | US | disclosed |
| US-20170166533-A1 | ETHERS, SECONDARY AMINES AND DERIVATIVES THEREOF AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. | 2017-06-15 | — | — | US | disclosed |
| US-20120295938-A1 | ETHERS, SECONDARY AMINES AND DERIVATIVES THEREOF AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. | 2012-11-22 | — | — | US | disclosed |
| US-8148418-B2 | Ethers, secondary amines and derivatives thereof as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2012-04-03 | — | — | US | disclosed |
| US-8148418-B2 | Ethers, secondary amines and derivatives thereof as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2012-04-03 | — | — | US | disclosed |
| US-8148418-B2 | Ethers, secondary amines and derivatives thereof as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2012-04-03 | — | — | US | disclosed |
| US-20090186895-A1 | ETHERS, SECONDARY AMINES AND DERIVATIVES THEREOF AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2009-07-23 | — | — | US | disclosed |
| US-20090186895-A1 | ETHERS, SECONDARY AMINES AND DERIVATIVES THEREOF AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2009-07-23 | — | — | US | disclosed |
| US-20090186895-A1 | ETHERS, SECONDARY AMINES AND DERIVATIVES THEREOF AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2009-07-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170166533-A1 | ETHERS, SECONDARY AMINES AND DERIVATIVES THEREOF AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | HTR2A, HTR5A, HTR2C | HTR2A 1/4885HTR2C 3/4885KCNH2 1018/4885 |
| US-20090186895-A1 | ETHERS, SECONDARY AMINES AND DERIVATIVES THEREOF AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | HTR2A, HTR5A, HTR2C | HTR2A 1/4885HTR2C 3/4885KCNH2 1018/4885 |
| US-10450276-B2 | Ethers, secondary amines and derivatives thereof as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto | HTR2A, HTR5A, HTR2C | HTR2A 1/4885HTR2C 3/4885KCNH2 1018/4885 |
| US-20200247755-A1 | ETHERS, SECONDARY AMINES AND DERIVATIVES THEREOF AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | HTR2A, HTR5A, HTR2C | HTR2A 1/4885HTR2C 3/4885KCNH2 1018/4885 |
| US-20140163032-A1 | ETHERS, SECONDARY AMINES AND DERIVATIVES THEREOF AS MODULATORS OF THE 5-HT 2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | HTR2A, HTR5A, HTR2C | HTR2A 1/4885HTR2C 3/4885KCNH2 737/4885 |
| US-20120295938-A1 | ETHERS, SECONDARY AMINES AND DERIVATIVES THEREOF AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | HTR2A, HTR5A, HTR2C | HTR2A 1/4885HTR2C 3/4885KCNH2 723/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.